WallStreetZenWallStreetZen

NASDAQ: ME
23andme Holding Co Stock

$2.69-0.06 (-2.18%)
Updated Feb 3, 2023
ME Price
$2.69
Fair Value Price
$3.60
Market Cap
$1.23B
52 Week Low
$2.02
52 Week High
$6.31
P/E
-3.74x
P/B
1.5x
P/S
4.32x
PEG
N/A
Dividend Yield
N/A
Revenue
$297.62M
Earnings
-$314.54M
Gross Margin
46.4%
Operating Margin
-107.46%
Profit Margin
-105.7%
Debt to Equity
0.27
Operating Cash Flow
-$206M
Beta
1.61
Next Earnings
Feb 10, 2023
Ex-Dividend
N/A
Next Dividend
N/A

ME Overview

23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.

Zen Score

Industry Average (30)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ME scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ME ($2.69) is undervalued by 25.35% relative to our estimate of its Fair Value price of $3.60 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ME ($2.69) is significantly undervalued by 25.35% relative to our estimate of its Fair Value price of $3.60 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
ME is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ME due diligence checks available for Premium users.

Be the first to know about important ME news, forecast changes, insider trades & much more!

ME News

Valuation

ME fair value

Fair Value of ME stock based on Discounted Cash Flow (DCF)
Price
$2.69
Fair Value
$3.60
Undervalued by
25.35%
ME ($2.69) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ME ($2.69) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ME is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ME price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-3.74x
Industry
37.84x
Market
15.09x

ME price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.5x
Industry
4.54x
ME is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ME's financial health

Profit margin

Revenue
$75.7M
Net Income
-$66.1M
Profit Margin
-87.3%
ME's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ME's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$1.0B
Liabilities
$221.4M
Debt to equity
0.27
ME's short-term assets ($506.21M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ME's short-term assets ($506.21M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ME's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$72.9M
Investing
-$2.1M
Financing
$5.6M
ME's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ME vs Diagnostic & Research Stocks

TickerMarket Cap1d %P/EP/B
ME$1.23B-2.18%-3.74x1.50x
RDNT$1.24B-0.51%179.58x3.95x
NRC$1.14B+0.54%33.34x16.88x
OPK$1.07B-3.47%-3.09x0.66x
FLGT$1.07B-0.17%4.03x0.83x

23andme Holding Co Stock FAQ

What is 23andme Holding Co's quote symbol?

NASDAQ: ME) 23andme Holding Co trades on the NASDAQ under the ticker symbol ME. 23andme Holding Co stock quotes can also be displayed as NASDAQ: ME.

If you're new to stock investing, here's how to buy 23andme Holding Co stock.

What is the 52 week high and low for 23andme Holding Co (NASDAQ: ME)?

(NASDAQ: ME) 23andme Holding Co's 52-week high was $6.31, and its 52-week low was $2.02. It is currently -57.37% from its 52-week high and 33.17% from its 52-week low.

How much is 23andme Holding Co stock worth today?

(NASDAQ: ME) 23andme Holding Co currently has 455,484,782 outstanding shares. With 23andme Holding Co stock trading at $2.69 per share, the total value of 23andme Holding Co stock (market capitalization) is $1.23B.

23andme Holding Co stock was originally listed at a price of $9.91 in Oct 2, 2020. If you had invested in 23andme Holding Co stock at $9.91, your return over the last 2 years would have been -72.86%, for an annualized return of -47.9% (not including any dividends or dividend reinvestments).

How much is 23andme Holding Co's stock price per share?

(NASDAQ: ME) 23andme Holding Co stock price per share is $2.69 today (as of Feb 3, 2023).

What is 23andme Holding Co's Market Cap?

(NASDAQ: ME) 23andme Holding Co's market cap is $1.23B, as of Feb 6, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

23andme Holding Co's market cap is calculated by multiplying ME's current stock price of $2.69 by ME's total outstanding shares of 455,484,782.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.